ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$20.29 USD
+0.72 (3.68%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $20.22 -0.07 (-0.34%) 7:22 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.29 USD
+0.72 (3.68%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $20.22 -0.07 (-0.34%) 7:22 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Zacks News
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
by Zacks Equity Research
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
by Zacks Equity Research
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug
by Zacks Equity Research
The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.
Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio
by Zacks Equity Research
Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
by Zacks Equity Research
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Apellis (APLS) Kindles Acquisition Interest Per Bloomberg
by Zacks Equity Research
Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 5.56% and 41.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
Merck (MRK) Reports Detailed Data From PAH Study on Sotatercept
by Zacks Equity Research
Merck & Co. (MRK) announces detailed data from the phase III STELLAR study of sotatercept for the treatment of pulmonary arterial hypertension in adults.
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues beat estimates.
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.
Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues
by Zacks Equity Research
Acadia Pharmaceuticals (ACAD) reports mixed results for the fourth quarter of 2022, recording wider-than-expected loss per share and better-than-expected revenue figures owing to the sales of Nuplazid.
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly
Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ
by Zacks Equity Research
Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.